Therefore, we explore the role of PDE5-Is as complementary to the conventional treatment of symptomatic BPH; we provide the suggested biological procedures involved in the association between PDE5-I use and improvement in LUTS; and we propose new approaches to this topic. The gene discussed is PDE5A; the disease is benign prostatic hyperplasia.